Oxaliplatin Teva

Oxaliplatin, the active ingredient in Oxaliplatin Teva, is a platinum‑based chemotherapy agent presented as a sterile solution for intravenous infusion use. It is employed in the treatment of colorectal cancer and related solid tumours in adult patients. GNH USA supplies Oxaliplatin Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

GNH USA supplies Oxaliplatin Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres, hospitals and pharmacies worldwide.

Oxaliplatin Teva is a platinum‑based chemotherapeutic that acts on rapidly dividing cancer cells, particularly within the colorectal cancer pathway.

- Colorectal cancer: improves progression‑free survival when combined with fluorouracil and leucovorin. - Gastric cancer: used in combination regimens for advanced disease. - Pancreatic cancer: contributes to tumour response as part of multi‑drug protocols.

Oxaliplatin Teva may cause a range of adverse reactions, most of which are dose‑dependent and reversible.

Common Side Effects: - Nausea and vomiting: mild to moderate gastrointestinal upset. - Peripheral neuropathy: tingling or numbness, often transient. - Fatigue: generalized tiredness during treatment cycles. - Diarrhoea: loose stools that may require supportive care. - Thrombocytopenia: reduced platelet count, increasing bleeding risk. - Elevated liver enzymes: mild, transient rise in hepatic transaminases.

Serious or Rare Side Effects: - Severe neuropathy: persistent sensory loss that may be irreversible. - Anaphylactic reactions: acute hypersensitivity requiring emergency intervention. - Severe neutropenia: markedly low neutrophil count, raising infection risk. - Cardiac arrhythmias: irregular heart rhythms observed in rare cases. - Acute pulmonary toxicity: inflammation of lung tissue requiring prompt treatment. - Hemolytic‑type transfusion reactions: rare immune‑mediated haemolysis.

Oxaliplatin Teva should be administered under the supervision of qualified oncology professionals, with appropriate monitoring and supportive care.

- Renal function assessment: evaluate creatinine clearance before each infusion. - Hepatic function monitoring: check liver enzymes and bilirubin regularly. - Neuropathy surveillance: assess sensory changes at each visit. - Hematologic monitoring: complete blood count performed before each cycle. - Premedication: consider anti‑emetic prophylaxis to reduce nausea. - Store at ambient temperature: keep in original container, protect from light and moisture.

Oxaliplatin Teva may interact with several concomitant medications, influencing efficacy or toxicity.

Major Interactions (Avoid): - Aminoglycoside antibiotics: increase risk of nephrotoxicity. - High‑dose vitamin C: may reduce platinum‑drug activity.

Moderate Interactions (Monitor Closely): - Anticoagulants anticoants: may enhance bleeding risk. - Loop diuretics: potentiate electrolyte disturbances. - NSAIDs: increase risk of renal impairment. - CYP C‑